Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients
Chaojun Liu,Zhen Zhang,Yu Ping,Guohui Qin,Kai Zhang,Nomathamsanqa Resegofetse Maimela,Lan Huang,Shengli Yang,Yi Zhang
DOI: https://doi.org/10.2147/CMAR.S238174
2020-06-10
Cancer Management and Research
Abstract:Chaojun Liu, 1, * Zhen Zhang, 1, * Yu Ping, 1 Guohui Qin, 1– 3 Kai Zhang, 1 Nomathamsanqa Resegofetse Maimela, 1 Lan Huang, 1 Shengli Yang, 1 Yi Zhang 1– 3 1 Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, People's Republic of China; 2 Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, People's Republic of China; 3 Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan 450052, People's Republic of China *These authors contributed equally to this work Correspondence: Yi Zhang; Shengli Yang Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, 1th Jianshe Road, Zhengzhou, Henan 450052, People's Republic of China +86-371-6691-5320 ; +86-371-6691-2993 Email yizhang@zzu.edu.cn; slyang@sibs.ac.cn Background: Programmed cell death protein-1 (PD-1) blockade therapy is one of the most remarkable immunotherapy strategies in many solid tumors, excluding glioma. The PD-1 expression, immune characteristics, and prognosis relevance in glioma remain poorly understood. Patients and Methods: RNA sequencing (RNA-seq) and mRNA microarray data were obtained for 325 and 301 glioma patients, respectively, from the Chinese Glioma Genome Atlas (CGGA) database. We analyzed the expression profile of PDCD1 (encoding PD-1) according to the different grade, isocitrate dehydrogenase ( IDH ) mutation status, and molecular subtype of glioblastoma. Gene ontology (GO) analyses were performed to explore biological processes of PD-1-related genes. Survival analysis was conducted using the Kaplan–Meier method. The findings were validated using The Cancer Genome Atlas (TCGA) RNA-seq data from 697 glioma samples. We also confirmed the PDCD1 gene expression feature and survival relevance in our own cohort of 73 glioma patients. R language was used for statistical analysis and generating figures. Results: PDCD1 was enriched in glioblastoma (WHO, grade IV), IDH wild-type glioma and mesenchymal glioblastoma in CGGA and TCGA datasets; similar results were validated in our own patient cohort. GO analysis revealed that PDCD1 -related genes were involved in inflammation immune responses and T cell-mediated immune responses in glioma. Circos plots indicated that PDCD1 was positively associated with CD28, ICOS , and the inhibitory checkpoint molecules CTLA4, HAVCR2, TIGIT , and LAG3 . Patients with PDCD1 upregulation had much shorter overall survival. Conclusion: PDCD1 upregulation was found in more malignant phenotypes of glioma and indicated a worse prognosis. Immunotherapy of targeting PD-1 or combined with other checkpoint molecules (eg, TIM-3, LAG-3, or TIGIT) blockade may represent a promising treatment strategy for glioma. Keywords: programmed cell death 1, glioma, The Cancer Genome Atlas, survival analysis, immunotherapy, costimulatory, inhibitory T-cell receptors
oncology